Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.
Eligibility criteria
Qualifiers
Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole: oral suspension (200mg three times daily) or tablet (300mg once daily) to prevent invasive fungal infections
Disqualifiers
Gastroparesis
Vomiting or diarrhea within 2 hours after intake of posaconazole
Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...
Age under 18 years
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
55 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov